Avistone is a dedicated oncology company with a focus on developing innovative therapies to address the significant unmet medical needs of patients globally. The company boasts an extensive pipeline that includes two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage. Avistone's lead asset, PLB1001, is a small-molecule inhibitor targeting MET tyrosine kinase activity, particularly...
Avistone is a dedicated oncology company with a focus on developing innovative therapies to address the significant unmet medical needs of patients globally. The company boasts an extensive pipeline that includes two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage. Avistone's lead asset, PLB1001, is a small-molecule inhibitor targeting MET tyrosine kinase activity, particularly addressing aberrant activity associated with METexon14 skipping genetic alterations in NSCLC tumors and other solid tumors.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.